Janux Therapeutics, Inc. (NASDAQ:JANX) Receives $91.89 Consensus PT from Analysts

Janux Therapeutics, Inc. (NASDAQ:JANX) has been given an average recommendation of “Buy” by the twelve brokerages that are covering the firm, MarketBeat reports. One analyst has rated the stock with a hold rating, nine have assigned a buy rating and two have given a strong buy rating to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $91.89.

Separately, Raymond James Financial started coverage on shares of Janux Therapeutics in a research report on Friday, July 11th. They issued an “outperform” rating and a $65.00 target price for the company.

Insider Activity

In related news, insider Andrew Hollman Meyer sold 3,333 shares of Janux Therapeutics stock in a transaction dated Thursday, May 1st. The shares were sold at an average price of $32.03, for a total transaction of $106,755.99. Following the completion of the sale, the insider owned 82,139 shares of the company’s stock, valued at approximately $2,630,912.17. The trade was a 3.90% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. 8.10% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Janux Therapeutics

Institutional investors have recently made changes to their positions in the stock. RA Capital Management L.P. raised its holdings in shares of Janux Therapeutics by 13.1% during the 4th quarter. RA Capital Management L.P. now owns 10,365,652 shares of the company’s stock worth $554,977,000 after buying an additional 1,200,000 shares in the last quarter. Paradigm Biocapital Advisors LP increased its stake in shares of Janux Therapeutics by 46.5% in the fourth quarter. Paradigm Biocapital Advisors LP now owns 3,515,986 shares of the company’s stock valued at $188,246,000 after buying an additional 1,115,412 shares during the period. Janus Henderson Group PLC lifted its stake in shares of Janux Therapeutics by 41.2% in the fourth quarter. Janus Henderson Group PLC now owns 3,562,402 shares of the company’s stock worth $190,617,000 after acquiring an additional 1,038,996 shares during the period. Adage Capital Partners GP L.L.C. lifted its position in shares of Janux Therapeutics by 47.6% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 3,061,750 shares of the company’s stock worth $163,926,000 after purchasing an additional 986,750 shares during the period. Finally, Price T Rowe Associates Inc. MD boosted its stake in shares of Janux Therapeutics by 596.3% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,109,978 shares of the company’s stock valued at $59,429,000 after purchasing an additional 950,557 shares during the last quarter. 75.39% of the stock is currently owned by institutional investors.

Janux Therapeutics Stock Down 4.9%

NASDAQ:JANX opened at $26.40 on Wednesday. Janux Therapeutics has a 52-week low of $22.48 and a 52-week high of $71.71. The firm has a market cap of $1.56 billion, a P/E ratio of -19.41 and a beta of 2.86. The business’s 50-day moving average price is $24.62 and its 200 day moving average price is $31.44.

Janux Therapeutics (NASDAQ:JANX) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.43) by $0.05. Sell-side analysts expect that Janux Therapeutics will post -1.38 EPS for the current year.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.